2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
Star0
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
- DrugBank Accession Number
- DB08398
- Background
PhIP (2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine) has been used in trials studying the basic science of Pancreas Cancer.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 224.2612
Monoisotopic: 224.106196404 - Chemical Formula
- C13H12N4
- Synonyms
- 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
- PhIP
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism AEstrogen receptor inhibitorHumans UNuclear receptor coactivator 2 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyridines and derivatives
- Sub Class
- Phenylpyridines
- Direct Parent
- Phenylpyridines
- Alternative Parents
- Imidazopyridines / N-substituted imidazoles / Benzene and substituted derivatives / Aminoimidazoles / Heteroaromatic compounds / Azacyclic compounds / Primary amines / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- 3-phenylpyridine / Amine / Aminoimidazole / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Heteroaromatic compound / Hydrocarbon derivative / Imidazole
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- primary amino compound, imidazopyridine (CHEBI:76290)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 909C6UN66T
- CAS number
- 105650-23-5
- InChI Key
- UQVKZNNCIHJZLS-UHFFFAOYSA-N
- InChI
- InChI=1S/C13H12N4/c1-17-11-7-10(9-5-3-2-4-6-9)8-15-12(11)16-13(17)14/h2-8H,1H3,(H2,14,15,16)
- IUPAC Name
- 1-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2-amine
- SMILES
- CN1C(N)=NC2=NC=C(C=C12)C1=CC=CC=C1
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0041008
- KEGG Compound
- C16038
- PubChem Compound
- 1530
- PubChem Substance
- 99444869
- ChemSpider
- 1476
- ChEBI
- 76290
- ChEMBL
- CHEMBL1213271
- ZINC
- ZINC000001850101
- PDBe Ligand
- PIQ
- Wikipedia
- 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
- PDB Entries
- 1hz0 / 2qxm
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data1 Withdrawn Basic Science Pancreatic Cancer 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.416 mg/mL ALOGPS logP 2.27 ALOGPS logP 2.09 Chemaxon logS -2.7 ALOGPS pKa (Strongest Basic) 5.12 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 56.73 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 68.59 m3·mol-1 Chemaxon Polarizability 24.68 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.925 Caco-2 permeable + 0.8867 P-glycoprotein substrate Non-substrate 0.6643 P-glycoprotein inhibitor I Non-inhibitor 0.7789 P-glycoprotein inhibitor II Non-inhibitor 0.6297 Renal organic cation transporter Non-inhibitor 0.7021 CYP450 2C9 substrate Non-substrate 0.8413 CYP450 2D6 substrate Non-substrate 0.8509 CYP450 3A4 substrate Non-substrate 0.5971 CYP450 1A2 substrate Inhibitor 0.9493 CYP450 2C9 inhibitor Non-inhibitor 0.946 CYP450 2D6 inhibitor Inhibitor 0.7174 CYP450 2C19 inhibitor Inhibitor 0.5665 CYP450 3A4 inhibitor Inhibitor 0.5987 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.601 Ames test AMES toxic 0.883 Carcinogenicity Non-carcinogens 0.9431 Biodegradation Not ready biodegradable 0.9883 Rat acute toxicity 2.4617 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9194 hERG inhibition (predictor II) Non-inhibitor 0.5736
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 159.7724608 predictedDarkChem Lite v0.1.0 [M-H]- 159.8604608 predictedDarkChem Lite v0.1.0 [M-H]- 159.8866608 predictedDarkChem Lite v0.1.0 [M-H]- 151.0447 predictedDeepCCS 1.0 (2019) [M+H]+ 159.6991608 predictedDarkChem Lite v0.1.0 [M+H]+ 159.8158608 predictedDarkChem Lite v0.1.0 [M+H]+ 159.7075608 predictedDarkChem Lite v0.1.0 [M+H]+ 153.44026 predictedDeepCCS 1.0 (2019) [M+Na]+ 160.2589608 predictedDarkChem Lite v0.1.0 [M+Na]+ 160.1993608 predictedDarkChem Lite v0.1.0 [M+Na]+ 160.2242608 predictedDarkChem Lite v0.1.0 [M+Na]+ 159.3528 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsEstrogen receptor
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3 (PubMed:17922032). Maintains neuronal survival in response to ischemic reperfusion injury when in the presence of circulating estradiol (17-beta-estradiol/E2) (By similarity)
- Specific Function
- 14-3-3 protein binding
- Gene Name
- ESR1
- Uniprot ID
- P03372
- Uniprot Name
- Estrogen receptor
- Molecular Weight
- 66215.45 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
2. DetailsNuclear receptor coactivator 2
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Transcriptional coactivator for steroid receptors and nuclear receptors (PubMed:23508108, PubMed:8670870, PubMed:9430642). Coactivator of the steroid binding domain (AF-2) but not of the modulating N-terminal domain (AF-1) (PubMed:23508108, PubMed:8670870, PubMed:9430642). Required with NCOA1 to control energy balance between white and brown adipose tissues (PubMed:23508108, PubMed:8670870, PubMed:9430642). Critical regulator of glucose metabolism regulation, acts as a RORA coactivator to specifically modulate G6PC1 expression (PubMed:23508108, PubMed:8670870, PubMed:9430642). Involved in the positive regulation of the transcriptional activity of the glucocorticoid receptor NR3C1 by sumoylation enhancer RWDD3 (PubMed:23508108). Positively regulates the circadian clock by acting as a transcriptional coactivator for the CLOCK-BMAL1 heterodimer (By similarity)
- Specific Function
- aryl hydrocarbon receptor binding
- Gene Name
- NCOA2
- Uniprot ID
- Q15596
- Uniprot Name
- Nuclear receptor coactivator 2
- Molecular Weight
- 159155.645 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at September 15, 2010 21:31 / Updated at August 26, 2024 19:22